2 recruiting, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Extrapulmonary Small Cell Carcinoma: new trials by email Literature Review of Extrapulmonary Small Cell Carcinoma trials Research Report on Extrapulmonary Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine - Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2026-10-16 | 2026-10-21 |
| AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA Durvalumab - Extrapulmonary Small Cell Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 66 | 2024-01-16 | 2024-06-18 |
| Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC Abemaciclib, - Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 2 | Completed | Case Comprehensive Cancer Center | 14 | 2020-01-13 | 2026-05-12 |
Small Cell Lung Carcinoma (2) · Carcinoma, Neuroendocrine (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Nerve Tissue (1)
Cyclophosphamide (1) · Etoposide (1) · abemaciclib (1) · durvalumab (1) · fludarabine (1)
Case Comprehensive Cancer Center (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · National Cancer Institute (NCI) (1)
United States (2) · Italy (1)
Afshin Dowlati, MD (1) · Angela Damato, MD (1) · Nicholas P Tschernia, M.D. (1)